Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider

18.06.24 23:45 Uhr

Werte in diesem Artikel
Aktien

26,62 EUR 0,19 EUR 0,72%

Indizes

PKT PKT

15.547,3 PKT 112,8 PKT 0,73%

2.725,8 PKT 12,2 PKT 0,45%

5.615,4 PKT 30,8 PKT 0,55%

Pfizer (PFE) closed at $27.41 in the latest trading session, marking a +1.59% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.25%. Elsewhere, the Dow gained 0.15%, while the tech-heavy Nasdaq added 0.03%.Prior to today's trading, shares of the drugmaker had lost 5.43% over the past month. This has lagged the Medical sector's gain of 0.11% and the S&P 500's gain of 3.34% in that time.The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company's upcoming EPS is projected at $0.45, signifying a 32.84% drop compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $13.21 billion, reflecting a 3.72% rise from the equivalent quarter last year.For the annual period, the Zacks Consensus Estimates anticipate earnings of $2.38 per share and a revenue of $60.66 billion, signifying shifts of +29.35% and +3.7%, respectively, from the last year.Investors should also take note of any recent adjustments to analyst estimates for Pfizer. Such recent modifications usually signify the changing landscape of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.63% lower. Currently, Pfizer is carrying a Zacks Rank of #3 (Hold).Investors should also note Pfizer's current valuation metrics, including its Forward P/E ratio of 11.36. Its industry sports an average Forward P/E of 14.43, so one might conclude that Pfizer is trading at a discount comparatively.We can also see that PFE currently has a PEG ratio of 1.06. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The average PEG ratio for the Large Cap Pharmaceuticals industry stood at 1.78 at the close of the market yesterday.The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 156, which puts it in the bottom 39% of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Where Will Stocks Go…If Biden Wins? If Trump Wins?The answers may surprise you.Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…1. Medical manufacturer has gained +11,000% in the last 15 years.2. Rental company is absolutely crushing its sector.3. Energy powerhouse plans to grow its already large dividend by 25%.4. Aerospace and defense standout just landed a potentially $80 billion contract.5. Giant Chipmaker is building huge plants in the U.S. Hurry, Download Special Report FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Pfizer

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Pfizer

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Pfizer Inc.

Analysen zu Pfizer Inc.

DatumRatingAnalyst
12.07.2024Pfizer BuyGoldman Sachs Group Inc.
11.07.2024Pfizer BuyJefferies & Company Inc.
10.07.2024Pfizer NeutralJP Morgan Chase & Co.
03.07.2024Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.05.2024Pfizer KaufenDZ BANK
DatumRatingAnalyst
12.07.2024Pfizer BuyGoldman Sachs Group Inc.
11.07.2024Pfizer BuyJefferies & Company Inc.
02.05.2024Pfizer KaufenDZ BANK
02.05.2024Pfizer BuyJefferies & Company Inc.
31.01.2024Pfizer BuyJefferies & Company Inc.
DatumRatingAnalyst
10.07.2024Pfizer NeutralJP Morgan Chase & Co.
03.07.2024Pfizer HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
01.05.2024Pfizer NeutralUBS AG
01.05.2024Pfizer NeutralJP Morgan Chase & Co.
12.04.2024Pfizer NeutralJP Morgan Chase & Co.
DatumRatingAnalyst
03.05.2018Pfizer VerkaufenDZ BANK
16.05.2017Pfizer SellCitigroup Corp.
27.11.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
28.08.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)
10.01.2012Pfizer verkaufenHamburger Sparkasse AG (Haspa)

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Pfizer Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"